10-Q – Quarterly report [Sections 13 or 15(d)]

Evelo Biosciences has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Evelo Biosciences, 2018, MAY 31, 2018, View Source [SID1234527513]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rigel to Present at Jefferies 2018 Global Healthcare Conference

On May 31, 2018 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) reported that Raul Rodriguez, the company’s president and chief executive officer, is scheduled to present a company overview at the Jefferies Global Healthcare Conference in New York City on Tuesday, June 5, 2018 at 10:30am EDT (Press release, Rigel, MAY 31, 2018, View Source;p=RssLanding&cat=news&id=2352484 [SID1234527005]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast of the presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel’s website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

AVEO Oncology to Present at the Jefferies 2018 Healthcare Conference

On May 31, 2018 AVEO Oncology (NASDAQ: AVEO) reported that Michael Bailey, president and chief executive officer, will present at the Jefferies 2018 Healthcare Conference in New York on Thursday, June 7, 2018 at 9:30 a.m. Eastern Time (Press release, AVEO, MAY 31, 2018, View Source;p=RssLanding&cat=news&id=2352456 [SID1234526988]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.

Navidea Biopharmaceuticals to Present at 8th Annual LD Micro Invitational Conference and Participate in the 2018 BIO International Convention

On May 30, 2018 Navidea Biopharmaceuticals (NYSE MKT: NAVB) ("Navidea" or "the Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, reported it will present at the 8th Annual LD Micro Invitational Conference in Bel-Air, CA being held June 4-6, 2018 (Press release, Navidea Biopharmaceuticals, MAY 30, 2018, View Source [SID1234526950]). Jed Latkin, Chief Financial and Operating Officer of Navidea, will be giving a corporate presentation focused on Navidea’s clinical programs. In additional, Michael Goldberg, M.D., Chief Executive Officer of Navidea, along with other members of management will attend the 2018 BIO International Convention in Boston, MA being held June 4-7, 2018 to participate in meetings with potential clinical and commercial partners, investors, and other parties.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: 8th Annual LD Micro Invitational
Presentation Date: Monday, June 4, 2018
Presentation Time: 1:00pm PT
Location: Luxe Sunset, Bel-Air, CA

The presentation at the LD Micro Invitational Conference will be webcast live and remain available for 90 days following the presentation. To access the webcast, please visit the Investors presentations tab of the Investors section of the Navidea website at www.navidea.com.

The LD Micro Invitational Conference is one of the nation’s largest independent conferences for small/micro-cap companies, with more than 230 names presenting to 1,000+ attendees. The conference will also feature a variety of speakers and panelists discussing topics of interest to investors and issuers, as well as evening social events.

The BIO International Convention (BIO) attracts 16,000+ biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. The Convention brings together a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.

To schedule a meeting with Navidea management at either conference, please contact Navidea Investor Relations at [email protected].

About BIO:

BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO’s blog chronicling "innovations transforming our world" and the BIO Newsletter is the organization’s bi-weekly email newsletter.

About LD Micro:

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. The firm hosts several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe. For those interested in attending, please contact David Scher at [email protected] or visit www.ldmicro.com for more information.

Affimed to Present at the Jefferies Global Healthcare Conference

On May 30, 2018 Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, reported that Dr. Adi Hoess, CEO, will present at the Jefferies Global Healthcare Conference on Wednesday, June 6, 2018 at 4:30 pm ET (Press release, Affimed, MAY 30, 2018, View Source [SID1234526969]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the conference presentation can be accessed through the "Events" section on the "Investors & Media" page of the Affimed website at www.affimed.com/events.php. A replay of the presentation will be available from Affimed’s website for 30 days following the conference.